-transparent.png){kind=logo}
A synthetic vasopressin analog, 1-desamino-8D-arginine vasopressin (DDAVP also known as desmopressin), was found to be highly effective in the treatment of seven children and one adult with vasopressin-sensitive diabetes insipidus. The average duration of action of DDAVP was 10 to 11 hours, and with proper adjustment of dose, the subjects were able to control their symptoms satisfactorily with one or two inhalations daily. The youngest child in whom adequate control was achieved was 2 years of age. All subjects found the use of intranasal DDAVP superior to other forms of therapy, and none experienced any known side-effects after six months of treatment. All subjects in this study are currently using 2.5 mug to 10 mug of DDAVP once or twice daily.
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
July 1975,
Harefuah,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
November 1978,
The Journal of pediatrics,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
July 1974,
British medical journal,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
January 1975,
La Nouvelle presse medicale,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
April 1974,
Schweizerische medizinische Wochenschrift,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
August 1975,
Nederlands tijdschrift voor geneeskunde,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
January 1975,
Pediatrie,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
March 1973,
Acta paediatrica Scandinavica,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
August 1973,
British medical journal,
W P Lee, and
B M Lippe, and
S H La Franchi, and
S A Kaplan
September 1977,
American journal of hospital pharmacy,
